𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Acute effects of immediate and controlled-release levodopa on mood in Parkinson's disease: A double-blind study

✍ Scribed by Jaime Kulisevsky; Berta Pascual-Sedano; Manel Barbanoj; Alexandre Gironell; Javier Pagonabarraga; Carmen García-Sánchez

Publisher
John Wiley and Sons
Year
2007
Tongue
English
Weight
141 KB
Volume
22
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.

✦ Synopsis

Mood fluctuations related to levodopa (LD) dosing are well-known psychiatric complications of Parkinson's disease (PD). No formal studies explored how affective response to LD relates to the type of motor response to oral LD (stable or wearing-off) and to different pharmacokinetic profiles of oral LD. We used an intrasubject randomized double-blind crossover design to study 14 patients (7 stable, 7 wearing-off) who were monitored for motor status, mood, anxiety, and plasma LD levels 1 hour before and 6 hours after an oral dose of immediate-release (IR) and controlled-release LD formulations. Analysis of the dose-response curves showed a significant interaction between the type of motor response and the type of LD. Only the wearing-off patients had a significant mood elevation, and this effect was only significant following challenge with IR LD. Motor status strongly correlated with LD plasma levels and anxiety but not with mood ratings. Mood changes in PD patients are related to the patient's type of motor response to oral LD and also to the kinetic profile of the LD formulation used for dopaminergic replacement.

📜 SIMILAR VOLUMES

Levodopa improves physical fatigue in Pa
Levodopa improves physical fatigue in Parkinson's disease: A double-blind, placebo-controlled, crossover study
✍ Jau-Shin Lou; Greg Kearns; Theodore Benice; Barry Oken; Gary Sexton; John Nutt 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 110 KB

## Abstract We quantitatively investigated the effect of carbidopa/levodopa (25/100) on physical fatigue during finger tapping and force generation in a double‐blind, placebo‐controlled crossover study. Parkinson's disease (PD) subjects were randomly assigned to carbidopa/levodopa or placebo for Vi

The effects of rasagiline on cognitive d
The effects of rasagiline on cognitive deficits in Parkinson's disease patients without dementia: A randomized, double-blind, placebo-controlled, multicenter study
✍ Hasmet A. Hanagasi; Hakan Gurvit; Pınar Unsalan; Hilal Horozoglu; Nese Tuncer; A 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 113 KB 👁 2 views

## Abstract Cognitive impairment can occur at all stages of Parkinson's disease. Rasagiline is a selective monoamine oxidase type‐B inhibitor that enhances central dopaminergic transmission. Dopamine is thought to be involved in certain cognitive processes such as working memory. We assessed the ef

Rotigotine transdermal patch in early Pa
Rotigotine transdermal patch in early Parkinson's disease: A randomized, double-blind, controlled study versus placebo and ropinirole
✍ Nir Giladi; Babak Boroojerdi; Amos D. Korczyn; David J. Burn; Carl E. Clarke; An 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 167 KB

## Abstract Rotigotine is a new, non‐ergot dopamine agonist formulated in a transdermal delivery system. The present study was to investigate the efficacy and safety of the rotigotine transdermal patch in the treatment of early Parkinson's disease. Patients (n = 561) were randomized to rotigotine,

Comparison of desipramine and citalopram
Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: A double-blind, randomized, placebo-controlled study
✍ David Devos; Kathy Dujardin; Isabelle Poirot; Caroline Moreau; Olivier Cottencin 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 118 KB 👁 2 views

## Abstract Depression is one of the most common psychiatric disturbances in Parkinson's disease (PD). Recent reviews have highlighted the lack of controlled trials and the ensuing difficulty in formulating recommendations for antidepressant use in PD. We sought to establish whether antidepressants

Safety of entacapone and apomorphine coa
Safety of entacapone and apomorphine coadministration in levodopa-treated Parkinson's disease patients: Pharmacokinetic and pharmacodynamic results of a multicenter, double-blind, placebo-controlled, cross-over study
✍ Jan C.M. Zijlmans; Berengere Debilly; Olivier Rascol; Andrew J. Lees; Franck Dur 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 146 KB 👁 1 views

## Abstract We investigated whether administration of the catechol‐__O__‐methyl transferase (COMT) inhibitor entacapone, at doses of 200 mg and 400 mg, alters the pharmacokinetics of apomorphine in Parkinson's disease patients experiencing severe motor fluctuations. In addition, the pharmacodynamic

Effect of levodopa on pain threshold in
Effect of levodopa on pain threshold in Parkinson's disease: A clinical and positron emission tomography study
✍ Christine Brefel-Courbon; Pierre Payoux; Claire Thalamas; Fabienne Ory; Isabelle 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 137 KB 👁 1 views

## Abstract Patients suffering from Parkinson's disease (PD) frequently experienced painful sensations that could be in part due to central modification of nociception. We compared pain threshold before and after administration of levodopa in PD patients and in controls, and investigated cerebral a